| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Plasmodium
DNMT-IN-3 targets DNA methyltransferase (DNMT) enzymes in Plasmodium falciparum, inhibiting DNA methylation. This epigenetic inhibition disrupts gene expression patterns essential for parasite survival, replication, and host cell invasion. The IC50 of 60 nM against P. falciparum demonstrates potent antiparasitic activity through DNMT inhibition. |
|---|---|
| ln Vitro |
In the Cell Thermal Shift Assay (CETSA), DNMT-IN-3 (Compound 70) (30 μM, 1 hour) stabilizes EIF3i protein in parasite protein extracts from 40°C to 52°C [1].
DNMT-IN-3 inhibits Plasmodium falciparum DNA methyltransferase with IC50 = 60 nM. It shows potent antimalarial activity against blood-stage parasites. In vitro, DNMT-IN-3 demonstrates dose-dependent inhibition of parasite growth with selectivity for P. falciparum DNMT over human DNMT enzymes. |
| ln Vivo |
In vivo, DNMT-IN-3 is predicted to show antimalarial efficacy in mouse malaria models. The compound's potent IC50 (60 nM) suggests potential for in vivo activity with adequate pharmacokinetic properties. Studies are needed to establish in vivo efficacy, optimal dosing, and safety profile.
|
| Enzyme Assay |
DNMT activity assay: incubate recombinant P. falciparum DNMT with DNMT-IN-3 (0.1 nM-100 μM) in assay buffer containing S-adenosylmethionine (SAM) and methylated DNA substrate. Detect methyltransferase activity by measuring incorporation of tritiated methyl groups from [³H]SAM. Calculate IC50 by nonlinear regression.
|
| Cell Assay |
Antimalarial activity assay: culture P. falciparum (3D7 strain) in human erythrocytes using RPMI 1640 medium with human serum. Add DNMT-IN-3 (0.1-1000 nM) in triplicate. Incubate for 48-72 h. Measure parasite growth by [³H]hypoxanthine incorporation or SYBR Green I fluorescence. Calculate IC50 values.
|
| Animal Protocol |
Mouse malaria model: infect mice with Plasmodium berghei or P. yoelii by intraperitoneal injection of parasitized erythrocytes. Administer DNMT-IN-3 (1-50 mg/kg, i.p. or p.o.) daily for 4 days. Monitor parasitemia by Giemsa-stained blood smears. Assess survival and determine ED50 compared to chloroquine.
|
| References |
| Molecular Formula |
C37H39N7O
|
|---|---|
| Molecular Weight |
597.75
|
| Exact Mass |
597.322
|
| CAS # |
1683516-27-9
|
| PubChem CID |
117976176
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
87.2
|
| Hydrogen Bond Donor Count |
3
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
45
|
| Complexity |
870
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CN(CCC1COC2=CC3=C(C=C2)C(=NC=N3)NCCNC4=CC=CC5=CC=CC=C54)CCNC6=CC=NC7=CC=CC=C76
|
| InChi Key |
HVPYXDODTWPWJZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C37H39N7O/c1-2-8-30-28(6-1)7-5-11-33(30)39-18-19-41-37-32-13-12-29(24-36(32)42-26-43-37)45-25-27-15-21-44(22-16-27)23-20-40-35-14-17-38-34-10-4-3-9-31(34)35/h1-14,17,24,26-27,39H,15-16,18-23,25H2,(H,38,40)(H,41,42,43)
|
| Chemical Name |
N-naphthalen-1-yl-N'-[7-[[1-[2-(quinolin-4-ylamino)ethyl]piperidin-4-yl]methoxy]quinazolin-4-yl]ethane-1,2-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6729 mL | 8.3647 mL | 16.7294 mL | |
| 5 mM | 0.3346 mL | 1.6729 mL | 3.3459 mL | |
| 10 mM | 0.1673 mL | 0.8365 mL | 1.6729 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.